New platform for therapeutic antibodies: launching of the IMABGEN Platform project, an innovative service for the generation of therapeutic antibodies

CALIXAR, Biotem and the CNRS/Université Claude Bernard Lyon 1 have been granted among the laureates of the 2021 “R&D Booster” program supported by the Region Auvergne-Rhône-Alpes and Bpifrance.

The partners will design and set up a native membrane antigens platform named IMABGEN for the discovery and the development of conformational monoclonal antibodies especially for immunotherapies.

CALIXAR will bring to the IMABGEN consortium its proprietary technologies to isolate and produce native and functional membrane antigens (GPCRs, receptors, transporters, enzymes, …).

Press Release – IMAGBEN 

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on LinkedIn